PROSCA/BLADDR 2023 | The future management of a T2N0M0 Uca from the radiation oncologist’s perspective

Paul Sargos, MD, Institut Bergonié, Bordeaux, France, shares insights on the future management of T2N0M0 urothelial carcinoma (UCa) from a radiation oncologist’s perspective. He highlights compelling data, including a retrospective analysis indicating that trimodal therapy—comprising surgery, radiotherapy, and chemotherapy—can achieve comparable oncological outcomes to radical cystectomy. Dr Sargos emphasizes the importance of patient selection and advocates for a multidisciplinary approach, involving urologists and medical oncologists, to tailor strategies for patients with localized non-muscle-invasive bladder cancer. The interview occurred at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR) 2023 in Malaga, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.